Acute Gout Flare Market

Key Highlights

• As per NHANES, the prevalence of Gout in the US men was 5.2% (5.9 million) and 2.7% (3.3 million) among women, in 2015-2016. The disease prevalence increased with age, with the lowest gout prevalence (0.7% or 0.6 million) in individuals aged 20 to 39 years and the highest (8.7% or 1.0 million) in individuals aged 80 years or older.

• The Acute Gout Flare epidemiology is segmented as Incident cases of Acute Gout Flare, Age-Specific cases of Acute Gout Flare, Gender-Specific cases of Acute Gout Flare in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Request a sample to unlock the CAGR of Acute Gout Flare Market

DelveInsight’s “Acute Gout Flare Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU4 (Germany, Spain, Italy, France), and the UK, and Japan.

The Acute Gout Flare market report provides current treatment practices, emerging drugs, Acute Gout Flare market share of the individual therapies, and current and forecasted Acute Gout Flare market size from 2019 to 2032, segmented by seven major markets. The report also covers current Acute Gout Flare treatment practices/algorithms and Acute Gout Flare unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain), and the United Kingdom
• Japan

Study period: 2019–2032

Acute Gout Flare Market Disease: Understanding and Treatment Algorithm

Gout is a form of inflammatory arthritis that is triggered by the crystallization of monosodium urate (MSU) inside the joints and is preceded by hyperuricemia. Gout progresses in 4 stages: Asymptomatic hyperuriceamia, Acute gout flare/attack, intercritical period, and if left untreated the disease reaches the Chronic tophaceous gout. In general, Gout is a manageable disease if diagnosed and treated properly.

Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, and decreased physical function as the patients experience symptoms such as severe pain and inflammation in one or more joints. Epidemiology studies shoe that Gout has become more prevalent over the past few decades, affecting over 3% of adults in the US.

Risk factors include genetics, age, gender, and diet. These factors may contribute to a high serum uric acid level, currently defined as a value of at least 6.8 mg per dL (405 μmol per L). Hyperuricemia is a primary risk factor for gout. Gout is more prevalent in males than females; It affects adults more than 60 years of age than younger population; Genetic pre-disposition for Gout, plays a vital role in disease progression. Excessive consumption of foods such as red meat, seafood, sugar-sweetened soft drinks, fructose and alcohol increase the risk of developing hyperuricemia.

According to American College of Rheumatology (ACR) guidelines, treatment of acute gout attacks involves pharmacological therapy with Non-Steroidal Anti—Inflammatory Drugs (NSAIDS) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution.

Acute Gout Flare Diagnosis

Microscopy of joint fluid is used less often, primarily in equivocal cases. In these situations, the diagnosis is established by aspiration of a joint or tophus and identification of needle-shaped monosodium urate crystals, preferably intracellular, with bright, negative birefringence on compensated polarized light microscopy. Ultrasonography, magnetic resonance imaging, and computed tomography are typically not necessary for diagnosis.

The differential diagnosis for acute monoarticular joint swelling includes pseudogout, infection, and trauma. Pseudogout, or calcium pyrophosphate deposition disease, can mimic gout in clinical appearance and may respond to nonsteroidal anti-inflammatory drugs (NSAIDs). Findings of calcium pyrophosphate crystals and normal serum uric acid levels on joint fluid analysis can differentiate pseudogout from gout. Septic arthritis may present without a fever or elevated white blood cell count; arthrocentesis is required to distinguish this condition from acute gout. Gout and septic arthritis can occur concomitantly, but this is rare. Trauma-associated joint swelling is typically identified by the history; however, trauma may result in an acute gout flare caused by increased concentrations of synovial urate. Imaging may be necessary to rule out fracture in a patient with gout-like symptoms after a joint injury.

Acute Gout Flare Treatment

To achieve rapid and complete resolution of symptoms, treatment of acute gout should commence within 24 hours of symptom onset. Oral corticosteroids, intravenous corticosteroids, NSAIDs, and colchicine are equally effective in treating acute flares of gout. NSAIDs are the first-line treatment. Indomethacin (Indocin) has historically been the preferred choice; however, there is no evidence it is more effective than any other NSAID. Intramuscular ketorolac appears to have similar effectiveness.Any oral NSAID may be given at the maximal dosage and continued for one to two days after relief of symptoms.

Acute Gout Flare Epidemiology

The Acute Gout Flare epidemiology section provides insights into historical and current Acute Gout Flare patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Gout Flare report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

• The general prevalence of gout is 1–4% of the general population. By gender, men are more predisposed to gout than females. In western countries, it occurs in 3–6% in men and 1–2% in women. In some countries, prevalence may increase up to 10%. Prevalence rises up to 10% in men and 6% in women more than 80 years old. Annual incidence of gout is 2.68 per 1000 persons. It occurs in men 2–6 folds more than women. Worldwide incidence of gout increases gradually due to poor dietary habits such as fast foods, lack of exercises, increased incidence of obesity and metabolic syndrome.

• As per National Health and Nutrition Examination Survey (NHANES), the prevalence of gout was 3.9% among US adults, which corresponds to an estimated 9.2 million adults in 2015–2016.

• The EPISER 2016 (Study of the prevalence of rheumatic diseases in adult population) study in Spain, says that gout has a prevalence of more than 2.6% in Spanish adult population.

• As per NHANES, the prevalence of Gout in the US men was 5.2% (5.9 million) and 2.7% (3.3 million) among women, in 2015-2016. The disease prevalence increased with age, with the lowest gout prevalence (0.7% or 0.6 million) in individuals aged 20 to 39 years and the highest (8.7% or 1.0 million) in individuals aged 80 years or older.

• The Acute Gout Flare epidemiology is segmented as Incident cases of Acute Gout Flare, Age-Specific cases of Acute Gout Flare, Gender-Specific cases of Acute Gout Flare in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Acute Gout Flare Epidemiology

The epidemiology segment also provides the Acute Gout Flare epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Acute Gout Flare Drug Chapters

The drug chapter segment of the Acute Gout Flare report encloses the detailed analysis of Acute Gout Flare marketed drugs and late-stage (Phase III and Phase II) Acute Gout Flare pipeline drugs. It also helps understand the Acute Gout Flare clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Acute Gout Flare Marketed Drugs

Note: Current therapies assessment will be provided in the full report

Acute Gout Flare Emerging Drugs

OLT1177 (Dapansutrile): Olatec Therapeutics

It is an investigational small molecule, new chemical entity that specifically binds to and blocks NLRP3 (nucleotide-binding and oligomerization domain [NOD]-, leucine rich repeat-, pyrin domain-containing 3), the sensor molecule integral in the formation of the NLRP3 inflammasome.

It is in Phase II clinical development and has been well tolerated and shown to improve clinical outcomes in patients with acute gout flare. The company has announced positive results in Phase IIa (Study OLT1177-05). This molecule represents the first known selective NLRP3 inhibitor to demonstrate clinical benefit, safety and a reduction in systemic inflammation.

DYV700: Dyve Biosciences

Dyve Biosciences received clearance from the US Food and Drug Administration to proceed with a Phase II trial of DYV-700, the company’s topically administered therapeutic being developed to reduce the pain and duration of an acute gout flare.

In an initial randomized double blind placebo controlled trial, DYV700 provided patients experiencing gout flares with fast-acting relief that mitigated pain in minutes vs. days with the existing standard of care.

Note: Detailed emerging therapies assessment will be provided in the full report

Acute Gout Flare Market Outlook

The increasing prevalence of Acute Gout Flare in almost all 7MM, rise in neonatal screening and diagnostic awareness, new upcoming novel gene-based therapies and regulatory programs to fasten lab-to-market process are projected to propel the market growth during the forecast period. However, the need for infant patients to test gene-based therapies and rare nature of Acute Gout Flare are likely to hamper clinical development of emerging therapies. Many emerging therapies are expected to cost a premium annual cost per patient in Acute Gout Flare market and hence, approaching reimbursement proactively can have a positive impact in ensuring successful product launch in this market.

Acute Gout treatment includes, first-line treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution. In most cases, acute attacks are followed by recurrent attacks with decreasing intercritical periods, leading to Chronic Gout. Chronic gout manifests by chronic synovitis, bony erosions, and cartilage damage and tophi formation.

The EULAR recommends considering IL-1 blockers for the management of gout flares in patients with frequent flares contraindicated to NSAIDs, colchicine and steroids (oral or injectable). Canakinumab, a long lasting antibody to IL-1 beta, has been approved by the European Medical Agency, following 2 RCT trials against intramuscular triamcinolone acetonide. In addition, Anakinra, an IL-1 receptor antagonist, is used off-label in these cases. ULDs (Urate Lowering Drugs) are used to maintain uric acid levels in blood.

Non-steroidal anti-inflammatory agents and COX-2 inhibitors – the mainstay of therapy of acute attacks of gout in patients who have no contra-indication to them. These medications include such agents as naproxen (Naprosyn), ibuprofen (Motrin), celecoxib (Celebrex), indomethacin (Indocin) and many others. These agents reliably decrease the inflammation and pain of gout.

Corticosteroids, such as prednisone and methylprednisolone (Medrol) are also used as first-line treatment for patients with liver metabolic disorders. They are administered either as oral tablets or as Parenteral, based on patient’s condition. Parenteral Corticosteroids used include methylprednisolone acetate (Depo-Medrol), triamcinolone (Aristospan), and betamethasone (Celestone)

Colchicine (Colcrys, Mitigare) is used in treatment of Gout. It is very specific in action to resolve Gout attacks.

Key findings

This section includes a glimpse of the Acute Gout Flare market in 7MM.

The United States: Acute Gout Flare Market Outlook

This section provides the total Acute Gout Flare market size and market size by therapies in the United States.

EU4 and the UK Countries: Acute Gout Flare Market Outlook

The total Acute Gout Flare market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Acute Gout Flare Market Outlook

The total Acute Gout Flare market size and market size by therapies in Japan are also mentioned.

Acute Gout Flare Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Acute Gout Flare market or expected to get launched in the market during the study period 2019–2032. The analysis covers Acute Gout Flare market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the Acute Gout Flare drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Acute Gout Flare Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Gout Flare’s key players involved in developing targeted therapeutics.

Acute Gout Flare Clinical Trial Development Activities

The acute gout flare clinical trials report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Acute Gout Flare emerging therapies.

Acute Gout Flare Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Acute Gout Flare domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Acute Gout Flare market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Acute Gout Flare unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Acute Gout Flare market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Acute Gout Flare Market Report Scope

• Descriptive overview of Acute Gout Flare, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Acute Gout Flare epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Acute Gout Flare, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Acute Gout Flare market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based Acute Gout Flare market forecasting determines the trends shaping and driving the global Acute Gout Flare market

Acute Gout Flare Market Report Highlights

• In the coming years, the Acute Gout Flare market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Gout Flare R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Acute Gout Flare therapies. The launch of emerging therapies will significantly impact the Acute Gout Flare market
• A better understanding of Acute Gout Flare pathogenesis will also contribute to the development of novel therapeutics for Acute Gout Flare
• Our in-depth analysis of the Acute Gout Flare pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Gout Flare Report Insights

• Patient-Based Acute Gout Flare Market Forecasting
• Therapeutic approaches
• Acute Gout Flare pipeline analysis
• Acute Gout Flare market size and trends
• Acute Gout Flare market opportunities
• Impact of upcoming therapies

Acute Gout Flare Report Key Strengths

• 11 years forecast
• 7MM Coverage
• Acute Gout Flare epidemiology segmentation
• Key cross competition
• KOL views
• Acute Gout Flare drugs uptake

Acute Gout Flare Report Assessment

• Current treatment practices
• Unmet needs
• Acute Gout Flare pipeline product profiles
• Acute Gout Flare market attractiveness

Key Questions

Acute Gout Flare market insights:

• What would be the Acute Gout Flare market growth till 2032, and what will be the resultant market size in 2032?
• What was the Acute Gout Flare drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Acute Gout Flare total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Acute Gout Flare market size during the forecast period (2019–2032)
• How would the unmet needs affect the Acute Gout Flare market dynamics and subsequent analysis of the associated trends?

Acute Gout Flare Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Acute Gout Flare?
• What is the historical and forecasted Acute Gout Flare patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, Spain, France, Italy), and the UK, and Japan?

Current Treatment Scenario, Acute Gout Flare Marketed Drugs, and Acute Gout Flare Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Acute Gout Flare in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Acute Gout Flare therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Gout Flare and its status, along with the challenges faced?

Reasons to Buy

• The patient-based Acute Gout Flare market forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Acute Gout Flare market
• Organize sales and marketing efforts by identifying the best opportunities for Acute Gout Flare in the US, Europe (Germany, Spain, Italy, France), and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors